HCV / Hepatitis

A global review demonstrates the potential depth of the impact of the COVID-19 pandemic on ongoing immunization delay and skepticism.

Several trial participants experienced concerning hepatobiliary events.

The federal agency’s reports shows decreases in both hepatitis A and B, but hepatitis C saw a significant increase during 2021. However, the investigators note the pandemic may have impacted statistics and progress towards goals.

Biotech company is developing a product for a potential functional cure of the virus.

The formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) is a once-daily treatment for children living with HIV and meant to reduce pill burden.

Investigators found that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

Associated with excessive alcohol use, cirrhosis is one condition that can affect the pediatric population in the absence of alcohol.

With low vaccine utilization rates, finding educational resources to inform the public and increase attention to this preventative measure is needed to increase vaccinations.

Unique challenges can affect the success of the shift from pediatric to adult care settings.

Study compares efficiency of expanding HCV screening for all persons with HIV to programs focused on those at higher risk of HCV.

Hepatitis B vaccine non-responders with chronic HCV infection were likely to respond and gain protection against HBV after HCV treatment.

Efforts to ramp up hepatitis B vaccination at birth and in infancy are crucial to controlling the disease in Africa, which accounted for 66% of new infections in 2019.

HCV infections during pregnancy increased 16-fold from 1998 to 2018 in US, with adverse maternal and infant outcomes linked to opioid epidemic.

For people living with chronic hepatitis D, the latest study results confirm the benefit of injections of this first-in-class entry inhibitor.

The CDC made this recommendation after reviewing relevant literature, and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.

This day reflects the importance of remembering people who have been affected by the disease as well as a reminder to remain safe and get tested.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

A company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b (HBV).

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

In a major breakthrough, Gilead’s remdesivir (Veklury) becomes the first COVID-19 antiviral to be FDA-approved for patients with severe renal disease.

Among people living with hepatitis C virus (HCV), viral clearance was only 34%. Cure rates were even lower among uninsured persons younger than 40.

The investigational therapy from Gilead showed effectiveness and safety at 96 weeks.

Liver education has been void in the school systems and children and young adults stand to gain enormously when provided with awareness around this essential organ.